New Clinical and Real-World Data for Genentech's Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...

Related Keywords

United States ,United Kingdom ,China ,California ,South San Francisco ,American ,Danielle Haney ,Adam Pryor ,Levi Garraway ,Loren Kalm ,Bruno Eschli ,Genentech ,Global Product Development ,Clinical Development Program ,American Society Of Retina Specialists ,Roche Group ,Retina Specialists ,Annual Meeting ,Global Product ,Disease Activity Criteria ,Dosing Interval Assignment ,Clinical Trial Patients With ,Study Design ,Underrepresented Patients With Diabetic Macular ,Diabetic Retinopathy Symposium ,Epiretinal Membrane Formation Over ,Late Breaking ,Reduces Macular Leakage ,Patients With ,Causes Rapid ,Sustained Intraocular Suppression ,Retinal Fluid Control With Faricimab ,Rapidly Improves Fluid Parameters ,Treatment Patterns ,Diabetic Macular Edema Treated ,Delivery System With Ranibizumab ,Continuous Treatment ,Additional Results From ,Presentation Session ,Uveitic Macular Edema ,Novel Intravitreal ,Preliminary Results From ,Infectious Diseases ,Clinical Development ,Important Safety Information ,Vabysmo Prescribing Information ,